Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19159122 | 0.94 | LMNA (0.42) | LMNAHTTSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6571556 | 0.92 | LMNA (0.41) | LMNAHTTSMN1; SMN2L3MBTL1KDR | |
| SCHEMBL294214 | 0.92 | LMNA (0.41) | LMNAHTTSMN1; SMN2L3MBTL1KDR | |
| SCHEMBL19608592 | 0.92 | LMNA (0.41) | LMNAHTTSMN1; SMN2L3MBTL1KDR | |
| SCHEMBL9625648 | 0.92 | LMNA (0.41) | LMNAHTTSMN1; SMN2L3MBTL1KDR | |
| SCHEMBL292775 | 0.87 | — | — | |
| SCHEMBL27396970 | 0.82 | LMNA (0.38) | LMNAHTTSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL10174575 | 0.82 | LMNA (0.42) | LMNAHTTSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL6938010 | 0.82 | LMNA (0.39) | LMNAHTTSMN1; SMN2L3MBTL1GAA | |
| SCHEMBL12460199 | 0.82 | LMNA (0.39) | LMNAHTTSMN1; SMN2L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12027668-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery including the same | LG ENERGY SOLUTION, LTD. (KR) | 2024-07-02 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-2952096-B1 | Amide compound, an arthropod pest control agent and a method for controlling arthropod pest | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9840517-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-2900655-B1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2017-05-10 | — | — | EP | disclosed |
| EP-2287161-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| CN-1154637-C | Method for producing substituted pyrazoles | �����ɷ� | 2004-06-23 | — | — | CN | disclosed |
| CN-1261351-A | Process for preparing substituted pyrazoles | BASF AG (DE) | 2000-07-26 | — | — | CN | disclosed |
| EP-0366329-B1 | Halogeno-4-methylpyrazoles and process for preparing the same | NISSAN CHEMICAL IND LTD (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5220028-A | Halogeno-4-methylpyrazoles | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0366328-B1 | PROCESS FOR PREPARING 4-METHYLPYRAZOLES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1993-05-19 | — | — | EP | disclosed |
| EP-0366329-A1 | Halogeno-4-methylpyrazoles and process for preparing the same | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366328-A1 | Process for preparing 4-methylpyrazoles | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | LMNA 981/4885HTT 167/4885SMN1; SMN2 1100/4885 |
| US-12027668-B2 | Non-aqueous electrolyte solution for lithium secondary battery and lithium secondary battery including the same | RER1, CACNA1E, NAF1 | LMNA 2149/4885HTT 3433/4885SMN1; SMN2 1551/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | LMNA 4573/4885HTT 204/4885SMN1; SMN2 311/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | LMNA 3109/4885HTT 3960/4885SMN1; SMN2 3555/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | LMNA 3018/4885HTT 4413/4885SMN1; SMN2 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.